Enliven Therapeutics to Present Data at SOHO 2025 Annual Meeting
ByAinvest
Monday, Aug 25, 2025 6:25 pm ET1min read
ELVN--
The oral session is titled "Session V: Chronic Myeloid Leukemia" and will be presented on Thursday, September 4, from 11:40 a.m. to 11:50 a.m. CDT. The poster session will take place on Wednesday, September 3, at 6:25 p.m. CDT, located at Hall B3, Level 3, with poster number CML-575 [2].
Enliven Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, focused on the discovery and development of small molecule therapeutics. The company aims to address unmet needs in oncology with a precision approach that improves survival and enhances overall well-being. The data presentation at SOHO 2025 is expected to provide insights into the efficacy and safety of ELVN-001 in treating CML [1][2].
References:
[1] https://www.stocktitan.net/news/ELVN/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-at51d7emlwqd.html
[2] https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-society-of-hematologic-oncology-soho-2025-annual-meeting-302538061.html
Enliven Therapeutics will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The data, previously presented at the European Hematology Association (EHA) 2025 Congress, will be presented in both an oral and a poster session. Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for oncology.
Enliven Therapeutics, Inc. (Nasdaq: ELVN) will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The trial focuses on ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated Chronic Myeloid Leukemia (CML). The data will be presented in both oral and poster formats by Dr. Michael J. Mauro on September 3-4, 2025, at the George R. Brown Convention Center in Houston. This presentation is an encore of previously presented data at the European Hematology Association (EHA) 2025 Congress [1][2].The oral session is titled "Session V: Chronic Myeloid Leukemia" and will be presented on Thursday, September 4, from 11:40 a.m. to 11:50 a.m. CDT. The poster session will take place on Wednesday, September 3, at 6:25 p.m. CDT, located at Hall B3, Level 3, with poster number CML-575 [2].
Enliven Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, focused on the discovery and development of small molecule therapeutics. The company aims to address unmet needs in oncology with a precision approach that improves survival and enhances overall well-being. The data presentation at SOHO 2025 is expected to provide insights into the efficacy and safety of ELVN-001 in treating CML [1][2].
References:
[1] https://www.stocktitan.net/news/ELVN/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-at51d7emlwqd.html
[2] https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-society-of-hematologic-oncology-soho-2025-annual-meeting-302538061.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet